Freestone Grove Partners LP Buys New Position in IQVIA Holdings Inc. $IQV

Freestone Grove Partners LP purchased a new position in shares of IQVIA Holdings Inc. (NYSE:IQV) during the 2nd quarter, Holdings Channel.com reports. The institutional investor purchased 200,320 shares of the medical research company’s stock, valued at approximately $38,706,000.

A number of other hedge funds and other institutional investors have also modified their holdings of the company. Man Group plc acquired a new position in shares of IQVIA in the second quarter valued at approximately $57,131,000. Roberts Glore & Co. Inc. IL acquired a new stake in IQVIA during the second quarter worth approximately $284,000. Jupiter Topco LLC acquired a new stake in IQVIA during the second quarter worth approximately $3,995,000. Stanley Capital Management LLC purchased a new stake in IQVIA in the 2nd quarter worth approximately $16,887,000. Finally, Hsbc Holdings PLC acquired a new position in IQVIA in the 2nd quarter valued at $60,904,000. 89.62% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at IQVIA

In related news, insider Bhavik Patel sold 1,855 shares of the stock in a transaction that occurred on Friday, July 31st. The shares were sold at an average price of $235.27, for a total transaction of $436,425.85. Following the completion of the sale, the insider owned 1,348 shares of the company’s stock, valued at approximately $317,143.96. This represents a 57.91% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Keriann Cherofsky sold 558 shares of the firm’s stock in a transaction that occurred on Wednesday, July 29th. The shares were sold at an average price of $245.21, for a total transaction of $136,827.18. Following the completion of the transaction, the insider owned 2,989 shares in the company, valued at $732,932.69. The trade was a 15.73% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders have sold 12,913 shares of company stock valued at $3,098,793. 1.70% of the stock is owned by company insiders.

IQVIA Trading Up 0.8%

IQV stock opened at $261.57 on Thursday. The company has a market cap of $43.05 billion, a price-to-earnings ratio of 32.45, a PEG ratio of 2.22 and a beta of 1.18. The company has a quick ratio of 0.71, a current ratio of 0.71 and a debt-to-equity ratio of 2.18. The business has a fifty day simple moving average of $218.41 and a 200-day simple moving average of $188.59. IQVIA Holdings Inc. has a 52 week low of $154.50 and a 52 week high of $262.51.

IQVIA (NYSE:IQV) last issued its earnings results on Tuesday, July 28th. The medical research company reported $3.15 earnings per share for the quarter, beating analysts’ consensus estimates of $3.03 by $0.12. IQVIA had a return on equity of 30.25% and a net margin of 8.10%.The firm had revenue of $4.37 billion for the quarter, compared to analysts’ expectations of $4.30 billion. During the same quarter last year, the firm earned $2.81 earnings per share. The firm’s revenue for the quarter was up 8.7% compared to the same quarter last year. IQVIA has set its FY 2026 guidance at 12.800-13.000 EPS. On average, equities research analysts expect that IQVIA Holdings Inc. will post 11.57 EPS for the current year.

IQVIA declared that its Board of Directors has approved a share buyback plan on Thursday, May 7th that allows the company to repurchase $2.00 billion in outstanding shares. This repurchase authorization allows the medical research company to reacquire up to 6.8% of its shares through open market purchases. Shares repurchase plans are often an indication that the company’s management believes its stock is undervalued.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently issued reports on the company. Weiss Ratings upgraded IQVIA from a “hold (c-)” rating to a “hold (c)” rating in a report on Wednesday, July 15th. Royal Bank Of Canada increased their target price on IQVIA from $221.00 to $247.00 and gave the stock an “outperform” rating in a research report on Wednesday, July 29th. TD Cowen raised their price target on IQVIA from $233.00 to $288.00 and gave the stock a “buy” rating in a research note on Wednesday, July 29th. Mizuho lifted their price target on IQVIA from $215.00 to $230.00 and gave the company an “outperform” rating in a report on Monday, July 13th. Finally, Stifel Nicolaus upped their price objective on shares of IQVIA from $220.00 to $276.00 and gave the company a “buy” rating in a research note on Wednesday, July 29th. One research analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and three have given a Hold rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $241.88.

IQVIA Company Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real?world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real?world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.